Skip to main content

Table 1 Basic characteristics between left hemicolon sparing and extensive resection

From: Surgical outcomes of left hemicolon sparing resection versus extensive resection in treating synchronous colorectal cancer involving the right-sided colon and sigmoid colon or rectum

Variable

LHS group

(n = 103)

EXT group

(n = 35)

P

Age, (years)

 ≤ 63

44 (42.7)

20 (57.1)

0.139

 > 63

59 (57.3)

15 (42.9)

 

Gender

 Female

38 (36.9)

10 (28.6)

0.372

 Male

65 (63.1)

25 (71.4)

 

BMI, mean ± SD, kg/m2

23.8 ± 3.4

24.8 ± 3.0

0.145

ASA physical status

 I–II

90 (87.4)

34 (97.1)

0.184

 III

13 (12.6)

1 (2.9)

 

Concomitant diseases

 No

45 (43.7)

15 (42.9)

0.932

 Yes

58 (56.3)

20 (57.1)

 

History of abdominal surgery

 No

81 (78.6)

26 (74.3)

0.594

 Yes

22 (21.4)

9 (25.7)

 

Preoperative chemotherapy

 No

101 (98.1)

35 (100.0)

1.000

 Yes

2 (1.9%)

0 (0.0)

 

The distance of rectal or sigmoid colon cancer from anal verge, cm

12 (3–30)

15 (3–32)

0.294

Tumor sizea, cm

  ≤ 5

56 (54.9)

18 (51.4)

0.722

  > 5

46 (45.1)

17 (48.6)

 

Tumor differentiation

 Well-moderate

53 (51.5)

21 (60.0)

0.381

 Poor

50 (48.5)

14 (40.0)

 

pT stage

 T1-T2

8 (7.8)

5 (14.3)

0.254

 T3-T4

95 (92.2)

30 (85.7)

 

pN stage

 N0

41 (39.8)

14 (40.0)

0.933

 N1

44 (42.7)

14 (40.0)

 

 N2

18 (17.5)

7 (20.0)

 

Stage

 I

7 (6.8)

4 (11.4)

0.619

 II

34 (33.0)

10 (28.6)

 

 III

62 (60.2)

21 (60.0)

 

Hb level

 < 120

49 (47.6)

16 (45.7)

0.944

 ≥ 120

36 (35.0)

12 (34.3)

 

 Unknown

18 (17.5)

7 (20.0)

 

Alb level

 < 40

50 (48.5)

13 (37.1)

0.312

 ≥ 40

35 (34.0)

12 (34.3)

 

 Unknown

18 (17.5)

10 (28.6)

 

CEA level

 ≤ 5

45 (43.7)

11 (31.4)

0.441

 > 5

32 (31.1)

13 (37.1)

 

 Unknown

26 (25.2)

11 (31.4)

 

CA19-9 level

 ≤ 37

64 (62.1)

20 (57.1)

0.881

 > 37

12 (11.7)

4 (11.4)

 

 Unknown

27 (26.2)

11 (31.4)

 
  1. Abbreviation: LHS left hemicolon sparing, EXT extensive resection, BMI body mass index, Hb hemoglobin, Alb albumin, CA19-9 carbohydrate antigen 19–9, CEA carcinoembryonic antigen, ASA American Society of Anesthesiologists
  2. aUnknown for one patient